NYXH
Nyxoah SA (NASDAQ)
Healthcare — Medical Instruments & Supplies
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Buy
2.0 / 5
4 analysts
$1.78
+$0.09 (+5.33%)
Target:
$8.35
(369.0%)
Sign in to add NYXH to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $177.87M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.48 |
| EPS (TTM) | $-2.43 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 498.90% |
| ROE | -129.97% |
| Debt/Equity | 100.58 |
| Recommendation | Buy 2.0 |
| Analyst Target | $8.35 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 80.5 |
| Beta | 0.89 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.59 |
| 52-Week Low | $1.26 |
| 50-Day Avg | $2.47 |
| 200-Day Avg | $4.04 |
| Avg Volume | 263.0K |
| Volume | 156.3K |
Performance Analysis
BULLISHNYXH shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.26), which could present a value opportunity.
-
RSI at 80.5 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 498.9% year-over-year.
+
Wall Street consensus is "Buy" from 4 analysts.
+
Average analyst target of $8.35 implies 369.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:24 UTC
Back to Screener Export Report